Given the significant role of NLRP3 inflammasome in the pathogenesis of DCM, targeted therapeutic agents for NLRP3 inflammasome have received much attention.​ Increasing evidence suggests that SGLT2 inhibitors exert their anti-inflammatory effects through the inhibition of the NLRP3 inflammasome (Takahashi 2022; Ke et al. 2022). Here, NLRP3 is linked to familial dilated cardiomyopathy.